Tag: NASH

Oxaliplatin-Based Adjuvant Chemotherapy for Rectal Cancer After Preoperative Chemoradiotherapy (ADORE): Long-Term Results of a Randomized Controlled Trial 1. Adjuvant FOLFOX improves disease-free survival in patients with pathologic Stage II or III rectal cancer after upfront surgery and preoperative chemoradiotherapy, but is associated with a higher rate of adverse events. Evidence...

Non-alcoholic steatohepatitis (NASH), the most common chronic liver disease in the United States, puts patients at increased risk of developing cirrhosis and hepatocellular carcinoma. Patients with NASH are also at an increased risk of experiencing cardiovascular events and overall mortality. Pegbelfermin (BMS-986036) is a PEGylated human fibroblast growth factor...

Pegbelfermin (BMS-986036), a PEGylated Fibroblast Growth Factor 21 Analogue, in Patients with Non-Alcoholic Steatohepatitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2a Trial Non-alcoholic steatohepatitis (NASH), the most common chronic liver disease in the United States, puts patients at increased risk of developing cirrhosis and hepatocellular carcinoma. Patients with NASH are also...

Image: CC/Nephron. Histology of NASH Key study points: NASH patients undergoing liver transplant had significantly longer operative times (402 vs. 322 minutes, p < .001) versus patients undergoing transplants for other reasons.  In multivariate regression analyses, NASH is not an independent predictor of prolonged length-of-stay after liver transplant Primer: Nonalcoholic Steatohepatitis (NASH) is a form...